The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?

作者信息

Lewis Russell E, Wiederhold Nathan P

出版信息

Clin Infect Dis. 2003 Sep 15;37(6):871-2. doi: 10.1086/377279.

DOI:10.1086/377279

PMID:12955666

Abstract

摘要

相似文献

The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?

Clin Infect Dis. 2003 Sep 15;37(6):871-2. doi: 10.1086/377279.

Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment.

Mycoses. 2011 Mar;54(2):91-8. doi: 10.1111/j.1439-0507.2009.01805.x.

Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.

J Med Assoc Thai. 2006 Nov;89 Suppl 5:S118-24.

Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.

Clin Adv Hematol Oncol. 2009 Apr;7(4):1-8.

[Amphotericin B. Lipid complex versus liposomes. Which, why, when?].

Enferm Infecc Microbiol Clin. 1997 Jan;15(1):1-3.

Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections?

Clin Infect Dis. 2004 Jan 15;38(2):303-4; author reply 306-7. doi: 10.1086/380843.

Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence.

Clin Infect Dis. 2003 Jun 1;36(11):1500-1. doi: 10.1086/374876.

Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule.

J Antimicrob Chemother. 2007 Jul;60(1):180-2. doi: 10.1093/jac/dkm147. Epub 2007 May 30.

Nephrotoxicity of amphotericin B desoxycholate.

Clin Infect Dis. 2001 Sep 15;33(6):915-6. doi: 10.1086/322716.

Acrocyanosis developed with amphotericin B deoxycholate but not with amphotericin B lipid complex.

Mycoses. 2007 May;50(3):242. doi: 10.1111/j.1439-0507.2007.01360.x.

引用本文的文献

In Vivo Efficacy of Amphotericin B against Four Clades.

J Fungi (Basel). 2022 May 11;8(5):499. doi: 10.3390/jof8050499.

Covid-associated pulmonary mucormycosis.

Lung India. 2022 Mar-Apr;39(2):100-101. doi: 10.4103/lungindia.lungindia_95_22.

Unpredictable In Vitro Killing Activity of Amphotericin B against Four Clades.

Pathogens. 2021 Aug 6;10(8):990. doi: 10.3390/pathogens10080990.

Outcomes of early anti-fungal therapy with aggressive surgical resection in pulmonary mucormycosis.

Lung India. 2021 Jul-Aug;38(4):314-320. doi: 10.4103/lungindia.lungindia_758_20.

Characteristics of pulmonary mucormycosis and the experiences of surgical resection.

J Thorac Dis. 2020 Mar;12(3):733-740. doi: 10.21037/jtd.2019.12.117.

Clinical pharmacokinetics of inhaled antimicrobials.

Clin Pharmacokinet. 2015 May;54(5):473-92. doi: 10.1007/s40262-015-0250-x.

Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Clin Pharmacokinet. 2014 May;53(5):429-54. doi: 10.1007/s40262-014-0139-0.

continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.

PLoS One. 2013 Oct 21;8(10):e77075. doi: 10.1371/journal.pone.0077075. eCollection 2013.

Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update.

Mycopathologia. 2009 Dec;168(6):313-27. doi: 10.1007/s11046-009-9193-9. Epub 2009 Mar 24.

Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles.

Pharm Res. 2008 Sep;25(9):2056-64. doi: 10.1007/s11095-008-9588-1. Epub 2008 Apr 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验